



**Contact:**

David Waldman or Natalya Rudman  
Crescendo Communications, LLC  
Email: [mlss@crescendo-ir.com](mailto:mlss@crescendo-ir.com)  
Tel: 212-671-1020

## **Milestone Scientific Receives CE Mark Approval for Epidural Injection System**

**LIVINGSTON, NJ, September 18, 2014 -- Milestone Scientific Inc. (OTCQB: MLSS)**, a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its subsidiary, Milestone Medical, has received CE Mark to market and sell its epidural injection system in Europe. The CompuFlo™ Epidural Computer Controlled Anesthesia System (CompuFlo™ Epidural Model 6000) is intended for the verification of needle tip placement in the lumbar epidural space in patients over age of 18 and the delivery of medication and other fluids in a controlled manner in the lumbar epidural space as part of an in-patient or out-patient procedure established by their Health Care Provider.

Leonard Osser, Chief Executive Officer of Milestone Scientific, stated, "CE approval for our subsidiary's epidural instrument follows the recent CE approval of its intra-articular instrument. CE approval is an important achievement and further validation of our technology as our subsidiary moves towards commercial sale of the epidural injection system. Our subsidiary's next steps involve securing strategic partners to distribute its products in Europe, as it has already done in the U.S. Injection technology has not changed meaningfully since the advent of the hypodermic syringe over 150 years ago. Millions of patients that require epidural drug delivery and millions of women who give birth each year choose not to have an epidural due primarily to safety concerns about the high risks associated with this injection. Epidurals represent a multi-billion dollar global market and we believe our technology can transform these injections from an art to a science."

Milestone's injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other application of controlling the pain that patients typically associate with injections.

### **About Milestone Scientific Inc.**

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: [www.milestonescientific.com](http://www.milestonescientific.com).

#### **Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*